Stocks Health care FATE
NASDAQ · Health careFate Therapeutics Inc (FATE)
Fate Therapeutics Inc brought in $4.8M of revenue over the twelve months to September 30, 2026, down 33.4% from a year earlier. It posted a net loss of $124.4M. In fiscal 2025 capital spending exceeded operating cash flow by $112M. At September 30, 2026 it held $43.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Fate Therapeutics Inc
- Net worth
- Fate Therapeutics Inc has a market value (market cap) of $232.5M at the latest share price, and shareholders' equity of $133M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $6.6M (-51.2% year on year), with a net loss of $136.3M. Over the 12 months to September 30, 2026: revenue $4.8M, net loss $124.4M.
- Cash flow
- In fiscal 2025 operations used $106.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Fate Therapeutics Inc's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Fate Therapeutics Inc does
Fate Therapeutics Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker FATE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $6.6M | -$136.3M | -$1.15 | -$112M |
| 2024 | $13.6M | -$186.3M | -$1.64 | -$123.6M |
| 2023 | $63.5M | -$160.9M | -$1.64 | -$138.4M |
| 2022 | $96.3M | -$281.7M | -$2.91 | -$283.8M |
| 2021 | $55.8M | -$212.2M | -$2.24 | -$213.6M |
| 2020 | $31.4M | -$173.4M | -$2.10 | -$44.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where FATE ranks in Health care
Latest SEC filings
What Fate Therapeutics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Activist stake changed SCHEDULE 13D/A
- November 5, 2026
- November 5, 2026
- November 5, 2026
- November 5, 2026
- September 28, 2026Other event 8-K
- August 13, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 9.2% to $2.1M versus the same quarter last year; diluted EPS -$0.25 versus -$0.29.
- August 13, 2026
- July 8, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Fate Therapeutics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $13.5K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Adawi KamalChief Financial Officer | Sold | 6,582 | $13.5K |
| August 4, 2026 | Valamehr BahramPresident and CEO, Director | Sold | 43,947 | $108.1K |
| August 4, 2026 | Tahl CindySee Remarks | Sold | 38,800 | $95.4K |
| May 20, 2026 | Valamehr BahramPresident and CEO, Director | Sold | 28,946 | $54.5K |
| May 20, 2026 | Tahl CindySee Remarks | Sold | 25,590 | $48.1K |
| May 6, 2026 | Tahl CindySee Remarks | Exercised options | 122,220 | $161.3K |
| May 6, 2026 | Tahl CindySee Remarks | Exercised options | 44,444 | $46.7K |
| May 5, 2026 | Rastetter William HDirector | Exercised options | 25,000 | $42.3K |
Who owns FATE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Redmile Group, LLC13D, may seek influence with 3 related filers | 14.99% | November 9, 2026 |
Largest institutional holders
Insiders
6 insiders reported holding 14,231,527 shares in total, about $27.6M at the last price.
| Holder | Shares |
|---|---|
| Redmile Group, LLCDirector, 10% owner | 12,884,27712,884,277 held indirectly |
| Valamehr BahramPresident and CEO, Director | 591,815 |
| Tahl CindySee Remarks | 589,355 |
| Adawi KamalChief Financial Officer | 93,418 |
| Rastetter William HDirector | 36,331 |
| Epstein Robert SDirector | 36,331 |
Questions about FATE
What does Fate Therapeutics Inc do?
Fate Therapeutics Inc is a company in the Health care sector, listed on NASDAQ as FATE. Its shares trade on NASDAQ under the ticker FATE.
What is Fate Therapeutics Inc's net worth?
Fate Therapeutics Inc has a market value (market cap) of $232.5M at the latest share price, and shareholders' equity of $133M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Fate Therapeutics Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $124.4M on revenue of $4.8M.
How much revenue does Fate Therapeutics Inc make?
Over the twelve months to September 30, 2026 Fate Therapeutics Inc reported revenue of $4.8M. That is 33.4% less than a year earlier.
When did Fate Therapeutics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the activist stake changed from November 9, 2026.
When is Fate Therapeutics Inc's next earnings report?
Fate Therapeutics Inc's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare FATE with
Follow FATE
Get an email when Fate Therapeutics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Fate Therapeutics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.